An area postrema GLP-1R to NTS pathway dissociates semaglutide-induced satiation, nausea and reduced food motivation from satiety

Imagine the brain as a vast, intricate control center that constantly monitors the body's needs, deciding when to eat, how much to enjoy food, and when to stop. For decades, scientists have known that a specific group of cells in the brainstem acts as a critical gateway for these signals. This area, sitting at the very base of the brain where it meets the spinal cord, is packed with receptors that listen to chemical messengers traveling through the blood. One of the most powerful of these messengers is a hormone called GLP-1. In recent years, drugs designed to mimic this hormone, such as semaglutide, have revolutionized the treatment of obesity. They work by telling the brain that the body is full, effectively turning down the volume on hunger. However, these drugs come with a significant catch: they frequently cause nausea and a general feeling of sickness, which leads many people to stop taking them. The big question for researchers has been whether the brain uses the same circuitry to create the feeling of fullness and the feeling of sickness, or if these are separate signals that happen to travel together. If they are separate, it might be possible to design future drugs that keep the weight-loss benefits while leaving the nausea behind.

A team of researchers at University College London has now mapped out these pathways with surprising precision, revealing that the brain does indeed use distinct circuits for these different effects. To understand how they did this, one must first look at how the brain reacts to a drug like semaglutide. When the drug enters the body, it travels to the brainstem and activates specific neurons. The researchers wanted to know exactly which neurons were turning on and what they were doing. They used a clever technique to "tag" only the neurons that were active at the exact moment the drug was administered. Think of this as taking a snapshot of the brain's activity, labeling the specific cells that were firing, and then being able to turn those same cells on again later, long after the drug had left the system. This allowed them to see what happens when only those specific, drug-activated cells are stimulated, without the presence of the drug itself.

The study began by carefully observing how mice responded to a single dose of semaglutide. The drug worked exactly as expected: it made the mice eat less, lose weight, and stop seeking out high-fat, sugary foods that they usually loved. It also made them avoid certain flavors, a behavior scientists use to measure nausea or aversion. The researchers then used their tagging method to identify the specific neurons that had been recruited by the drug. They found a clear split in the brainstem. In one small region called the area postrema, the drug directly activated neurons that had receptors for GLP-1. However, in the neighboring region called the nucleus of the solitary tract, the story was different. The drug activated a large number of neurons there, but most of them did not have GLP-1 receptors at all. This suggested that the drug was not acting directly on these cells, but rather was sending a signal from the first region to the second, turning them on indirectly.

To test this theory, the researchers performed a series of experiments where they could turn these tagged neurons on and off at will. When they reactivated the neurons in the second region—the ones that did not have GLP-1 receptors but had been turned on by the drug—the mice immediately showed the same symptoms as when they had the drug: they ate less, felt full, and developed a strong aversion to certain tastes. This proved that this specific group of neurons was responsible for the nausea and the immediate feeling of fullness. But the story became even more interesting when the researchers looked at the motivation to eat. They set up a task where mice had to work hard, pressing a lever many times to get a delicious treat. Semaglutide made the mice give up much sooner, showing they no longer wanted to work for the reward. When the researchers reactivated the same tagged neurons in the second region, the mice also lost their motivation to work for food. This indicated that the same circuit was responsible for both the sickness and the loss of desire for rewards.

The researchers then wanted to know where this signal started. They suspected the first region, the area postrema, was the trigger. To test this, they used a technique to silence the GLP-1 receptors in that first region before giving the drug. When they did this, the drug could no longer activate the neurons in the second region. Consequently, the mice no longer felt the nausea, and they did not lose their motivation to eat the tasty treats. However, the drug still made them eat less over a longer period and lose weight. This was a crucial discovery: it showed that the feeling of sickness and the loss of motivation for food are driven by a specific pathway starting in the area postrema and traveling to the second region. But the ability of the drug to make the mice feel full over time and lose weight was happening through a different route, one that did not require that specific pathway.

The team also looked closely at the chemical identity of the neurons in that second region to see if they could find specific types that might be responsible for the different effects. They found that the drug preferentially turned on neurons that produce two specific proteins, known as Adcyap1 and Th. These proteins have been linked in other studies to feelings of sickness and the regulation of reward. By identifying these specific cell types, the researchers have provided a clear map of the circuitry involved. They have shown that the brain does not use a single "off switch" for eating. Instead, it uses a complex network where one path controls the immediate feeling of fullness and the unpleasant side effects, while another path, which remains active even when the first is blocked, controls the longer-term reduction in appetite and body weight.

This work suggests that the unpleasant side effects of current weight-loss drugs are not an unavoidable consequence of the treatment. Because the circuit for nausea and the circuit for long-term weight loss are distinct, it may be possible to develop new therapies that target the specific pathway responsible for weight loss while sparing the pathway that causes nausea. The researchers did not claim to have found a cure for nausea, nor did they test these findings in humans. However, by demonstrating that these effects can be separated in the brain, they have opened a new door for understanding how these drugs work. The findings provide a concrete biological explanation for why some people struggle with the side effects of these medications and offer a roadmap for designing the next generation of treatments that could be both effective and easier to tolerate. The brain's control over eating is far more nuanced than previously thought, with different signals for different needs, and understanding these differences is the key to better medicine.